Efficacy of platelet-rich plasma in the treatment of thin endometrium: a meta-analysis of randomized controlled trials.

ABSTRACT

BACKGROUND: Thin endometrium (TE) is a common cause of female infertility in clinical practice. Platelet-rich Plasma (PRP) therapy becomes a novel treatment for thin endometrium; however, its clinical application remains controversial. This meta-analysis aims to evaluate the therapeutic effects of intrauterine autologous PRP infusion in women with thin endometrium through relevant randomized controlled trials (RCTs). METHODS: We systematically searched studies published in English from inception until June 2024 in databases such as PubMed, The Cochrane Library, Embase, Web of Science, and MEDLINE. Search terms included "Platelet-Rich Plasma," "thin endometrium," "endometrial thickness," "infertility," "pregnancy," "reproduction," and "adverse reactions". RCTs identified through the search were subjected to systematic review and meta-analysis, and data were analyzed using fixed-effects or random-effects models based on heterogeneity. RESULTS: Eight RCTs involving 678 patients with thin endometrium were included. Patients receiving PRP infusion demonstrated significantly superior outcomes compared to the control group in endometrial thickness (MD 1.23, 95%CI 0.87 to 1.59, P = 0.000), clinical pregnancy rate (RR 2.04, 95%CI 1.52 to 2.76, P = 0.000), live birth rate (RR 2.46; 95%CI 1.57 to 3.85, P = 0.000), cycle cancellation rate (RR 0.46, 95%CI 0.23 to 0.93, P = 0.000), and embryo implantation rate (RR 2.71; 95%CI 1.91 to 3.84, P = 0.000). There were no statistically significance in spontaneous abortion rate (RR 0.85, 95%CI 0.40 to 1.78, P = 0.659), chemical pregnancy rate (RR 1.84, 95%CI 0.72 to 4.72, P = 0.204) and endometrial vascular improvement rate (RR 1.10; 95%CI 0.89 to 1.38, P = 0.367) between the two groups. The limitations of this study includes that, we only included single lauguage for literature research, the sample size and heterogeneity which could cause criteria bias. CONCLUSION: Intrauterine PRP infusion may be an effective and safe treatment for women with thin endometrium. Further high-quality, large-sample, randomized controlled trials are needed to validate the reliability of our results. TRIAL REGISTRATION The review protocol is registered on PROSPERO with registration number CRD42023490421, and no modifications were made to the information provided at registration.